Global Anticoagulant Reversal Drugs Market Size By Product Type(Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine, and Others), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Geographic Scope And Forecast

Anticoagulant Reversal Drugs Market Size And Forecast

Anticoagulant Reversal Drugs Market size was valued at USD 1250.4 Million in 2021 and is projected to reach USD 3,652.8 Million by 2030, growing at a CAGR of 12.65% from 2022 to 2030.

The rising number of bleeding disorders, the introduction of new drugs, and the growing number of cases requiring anticoagulant therapies are some of the factors anticipated to foster market growth during the forecast period. The Global Anticoagulant Reversal Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Anticoagulant Reversal Drugs Market Definition

Anticoagulant drugs, often called "blood thinners," are pharmaceuticals that help reduce or prevent blood clots. They're frequently used to treat thrombolism. Now, if someone on an anticoagulant has a bleeding problem or accidentally takes too much, we have anticoagulant reversal drugs, like Idarucizumab, to undo the effects. These reversal drugs are crucial when dealing with things like unplanned surgery, an anticoagulant overdose, or uncontrolled bleeding. We use them for medical conditions like venous thromboembolism, AF, mechanical valve replacement, and other coagulation issues like antiphospholipid antibody syndrome and Factor V Leiden. Oral anticoagulants are popular and really good at preventing clots in people with AFib. However, because these medications can lead to bleeding in AFib patients, we sometimes need those anticoagulant reversal drugs to help stop it.

Global Anticoagulant Reversal Drugs Market Overview

So, what's really boosting the market for these kinds of treatments? Well, a big part of it is the fact that we're seeing more new therapies get the green light and hit the shelves. Plus, unfortunately, bleeding disorders are becoming more common, and more people need anticoagulants for various reasons. But another really important piece is the approval and launch of new reversal agents – things that can actually undo the effects of blood thinners. Take, for example, Andexxa by Portola Pharmaceuticals. Back in May 2018, the U.S. FDA gave it the thumbs-up, making it the very first antidote for factor Xa inhibitors. Think of it this way if someone on apixaban (Eliquis) or rivaroxaban (Xarelto) experiences serious bleeding that's hard to control, this reversal agent can step in. And they were planning to launch Andexxa pretty quickly, in early June, with an Early Supply Program using their first-generation product. Interestingly, they actually made their first sale of Ondexxya over in Europe in August 2019. Turns out, there were more patients taking Factor Xa inhibitors there than in the U.S.! And just to show how important this drug is considered, Andexxa even received FDA breakthrough therapy and U.S. orphan drug designations.

The rise in heart problems around the world is a big reason why we're seeing more demand for drugs that can reverse the effects of blood thinners, and that's really fueling market growth. Think about itThe “Global Health And Wellness Report” says that in 2018, about 40% of adults in the US had some kind of heart issue. Over in the UK, around 7.4 million people were living with heart and circulatory diseases, and sadly, more than 43,000 people under 75 died from these conditions every year, according to the British Heart Foundation Centre's 2018 report. And get thisthe Heart Disease and Stroke Statistics 2019 estimated that the lifetime risk of atrial fibrillation – that's an irregular heartbeat – is about 1 in 3 for white Americans.

However, the high cost of these reversal therapies is anticipated to restrain the market growth. As per the American College of Cardiology, 4-F PCC (Kcentra) helps in treating bleeding cases caused by rivaroxaban and apixaban and it is dosed at 50 units/kg. Its average wholesale price is USD 2.90 per unit, therefore treating a patient whose weight is 100 kg would cost around USD 14,500.

Global Anticoagulant Reversal Drugs MarketSegmentation Analysis

The Global Anticoagulant Reversal Drugs Market is segmented based on Product Type, Distribution Channel, and Geography.

Anticoagulant Reversal Drugs Market by Product Type

• Prothrombin Complex Concentrates• Phytonadione• Andexanet Alfa• Idarucizumab• Protamine• Others

Based on Product Type, the market is bifurcated into Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine, and Others. The idarucizumab segment accounted for the largest share of 36.77% and is anticipated to maintain its lead over the forecast period. This is attributed to the high revenue generation by idarucizumab in major geographies. Based on product type, the market is segmented into prothrombin complex concentrates, phytonadione (vitamin k), andexanet alfa, idarucizumab, protamine, and others.

 Anticoagulant Reversal Drugs Market by Distribution Channel

• Hospital Pharmacy• Retail Pharmacy• Online Pharmacy

Based on Distribution Channel, the market is bifurcated into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Hospital pharmacy dominated the market with a 49.2% share in 2019. This is attributed to the fact that hospitals are the primary centers for the diagnosis and treatment of different types of bleeding disorders. Uncontrolled bleeding during emergency conditions is further driving the segment. On the basis of the distribution channel, the market is classified into retail pharmacy, hospital pharmacy, and online pharmacy.

Anticoagulant Reversal Drugs Market by Geography

• North America• Europe• Asia Pacific• Rest of the world

On the basis of Geography, the Global Anticoagulant Reversal Drugs Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America held the largest revenue share of 39.62% in 2019 and is expected to maintain the lead throughout the forecast period. The U.S. accounted for the leading share in the North American market. Key factors contributing to its growth include high healthcare expenditure and favorable healthcare reimbursement policies for costly drugs. In addition, the easy availability of these reversal drugs during emergency conditions is driving the regional market.

Key Players

The “Global Anticoagulant Reversal Drugs Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Portola Pharmaceuticals; Boehringer Ingelheim; CSL Behring; Bausch Health Companies Inc.; Octapharma AG; Dr. Reddy’s Laboratories; AMAG Pharmaceuticals, Inc.; Pfizer, Inc.; SGPharma Pvt. Ltd.; and Alps Pharmaceutical Ind. Co., Ltd.

The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• April, 2018 – The US Food and Drug Administration (FDA) has given full approval to Boehringer Ingelheim’s Praxbind (idarucizumab), a particular reversal medication for Pradaxa (dabigatran etexilate mesylate). When reversing the anticoagulant effects of dabigatran is required for emergency surgery/urgent operations or in life-threatening or uncontrolled bleeding, Praxbind is prescribed for patients taking Pradaxa.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly

Reasons to Purchase this Report

We take a deep dive into the market, looking at both the numbers (quantitative) and the qualitative aspects, breaking it down by different segments based on things like economics and even other less obvious factors. For each of these segments and sub-segments, we'll give you the market value in USD Billion. You'll find out which region and segment we expect to see the fastest growth and which one will be the top dog. We'll also analyze each region, looking at how much of the product/service they use and what's influencing the market there. Plus, we'll cover the competitive scene, showing you the market ranking of the big players, along with what new products or services they've launched, who they've partnered with, how they've expanded, and who they've acquired in the last five years, complete with detailed company profiles – company overviews, insights, product comparisons, and SWOT analysis for all the major market players. Get a clear picture of where the market is now and where it's headed, considering recent events like growth opportunities, what's driving it forward, and the challenges and limitations in both new and established regions. We also provide an in-depth look at the market from all angles using Porter’s five forces analysis, offering insights into the value chain and the overall market dynamics, including upcoming growth opportunities. And don't forget, you'll get 6 months of analyst support after your purchase.

Customization of the Report

In case of any please connect with our sales team, who will ensure that your requirements are met.